ProCE Banner Activity

Frequently Asked Questions in Stroke Prevention With GLP-1 RAs in Patients With Diabetes

Clinical Thought

An expert addresses key questions related to the mechanisms of GLP-1 RAs contributing to stroke risk reduction in patients with diabetes, developing a treatment plan to mitigate stroke risk, and exploring other potential impacts of GLP-1 RAs.

Released: October 25, 2024

Expiration: October 24, 2025

Share

Faculty

Jay H. Shubrook

Jay H. Shubrook, DO, FACOFP, FAAFP

Professor
Department of Clinical Sciences and Community Health
Diabetologist
Touro University California College of Osteopathic Medicine
Vallejo, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Faculty Disclosure

Primary Author

Jay H. Shubrook, DO, FACOFP, FAAFP

Professor
Department of Clinical Sciences and Community Health
Diabetologist
Touro University California College of Osteopathic Medicine
Vallejo, California

Jay H. Shubrook, DO, FAAFP, FACOFP: consultant/advisor/speaker: Abbott, Bayer, Lilly, Madrigal, Novo Nordisk, Sanofi.